Symbiotec Q2 FY27 consolidated revenue Rs 280.0 cr; PAT Rs 52.0 cr
For Q2 FY27, Symbiotec Pharmalab reported consolidated revenue from operations of Rs 280.00 cr and PAT of Rs 52.00 cr, up from Rs 196.00 cr and Rs 19.00 cr in Q2 FY26.
Key takeaways
- Revenue from operations Rs 280.00 cr in Q2 FY27 vs Rs 196.00 cr in Q2 FY26
- PAT Rs 52.00 cr in Q2 FY27 compared with Rs 19.00 cr in Q2 FY26
- Profit before tax Rs 64.00 cr in Q2 FY27 vs Rs 33.00 cr in Q2 FY26
- H1 FY27 revenue from operations Rs 498.00 cr vs Rs 399.00 cr in H1 FY26
- H1 FY27 PAT Rs 66.00 cr compared with Rs 49.00 cr in H1 FY26
Q2 FY27 · consolidated
| Metric | Sep 2026 | Sep 2025 | Change |
|---|---|---|---|
| Revenue | Rs 280.00 cr | Rs 196.00 cr | +42.9% |
| PAT | Rs 52.00 cr | Rs 19.00 cr | +173.7% |
As reported in the filing. Figures are transcribed, not computed.
What the numbers show
- Net margin was 18.57% of revenue, up 887 bps from 9.69%.
Key numbers (consolidated, Q2 FY27 vs Q2 FY26)
- Revenue from operations: Rs 280.00 cr (Q2 FY26: Rs 196.00 cr)
- Profit before tax: Rs 64.00 cr (Q2 FY26: Rs 33.00 cr)
- Profit after tax (PAT): Rs 52.00 cr (Q2 FY26: Rs 19.00 cr)
According to the consolidated profit and loss presentation in the Q2 & H1FY27 Consolidated Profit & Loss Statement section of the investor presentation, Symbiotec Pharmalab Limited’s revenue from operations for the quarter ended Q2 FY27 was Rs 280.00 cr, compared with Rs 196.00 cr in Q2 FY26. Profit before tax for Q2 FY27 was Rs 64.00 cr, up from Rs 33.00 cr in the corresponding quarter of the previous year. Profit after tax (PAT) for Q2 FY27 stood at Rs 52.00 cr, versus Rs 19.00 cr in Q2 FY26.
The same statement shows that for the half year ended H1 FY27, revenue from operations was Rs 498.00 cr compared with Rs 399.00 cr in H1 FY26. Profit before tax for H1 FY27 was Rs 81.00 cr, compared with Rs 78.00 cr in H1 FY26, while profit after tax (PAT) for H1 FY27 was Rs 66.00 cr versus Rs 49.00 cr in H1 FY26.
The presentation attributes part of the Q2 FY27 performance to contributions from new businesses. In the Q2 & H1FY27 Financial Highlights and Q2 & H1FY27 Consolidated Profit & Loss Statement sections, the company notes milestone revenue of Rs. 53 crs in H1 from new businesses, operating expenses of Rs. 57 crs including ANDA filing fees, and depreciation of Rs. 24 crs related to these new businesses. It also discloses that reported EBITDA for Q2 and H1 FY27 includes a one-time impact of Rs. 3 crs towards IPO listing expenses debited to the profit and loss account.
The company further highlights, in the same consolidated profit and loss summary, that gross profit and EBITDA moved up year-on-year, and provides gross margin, reported EBITDA margin and PAT margin percentages for both Q2 and H1 FY27 versus the prior-year periods. However, the detailed statutory statement of financial results with line-by-line items such as total expenses, cost of materials, employee benefits, finance costs, depreciation and earnings per share is not included in this investor presentation extract.
Track Symbiotec Pharmalab Ltd
Cruxal reads every Symbiotec Pharmalab Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Get every filing that moves a stock
One email before the open, with the day's filings that actually shifted a price — the number, the source document and what the market did with it. Free, and you can unsubscribe from any issue.
Cruxal publishes market coverage for information only. Nothing here is investment advice.
